

## Special Issue

# WAMD: From Pathophysiology to Therapeutic Approaches Treatment

### Message from the Guest Editors

In this Special Issue on wet age-related macular degeneration (wAMD), we would like to explore new wAMD strategies to achieve better visual acuity and retina structural outcomes. Age-related macular degeneration is one of the main causes of visual impairment in elderly people. While the dry form has no approved treatment, several therapies have been proposed for the wAMD form to try to change the course of the disease and to improve visual acuity. The main treatments for wAMD are based on targeting choroidal neovascular membranes. The anti-VEGF agents have dramatically improved the disease outcome. In this issue, we are especially interested in examining consolidated and new anti-VEGF therapies and also considering the treatment protocols. Potential topics will include:

- Aflibercept, ranibizumab and brolicizumab treatment regimen
- Clinical trials for new drugs development
- Different types of wAMD and related disease outcomes
- Possible application of telemedicine in wAMD diagnosis and follow-up
- Nutritional supplements in wAMD

---

### Guest Editors

Dr. Enzo Maria Vingolo

Dr. Stefano Lupo

Dr. Francesca Toja

---

### Deadline for manuscript submissions

closed (30 April 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/50968](https://mdpi.com/si/50968)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).